Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Medical Developments International Debt-to-EBITDA?
Medical Developments InternationalASX:MVP -4.88%51 Debt-to-EBITDA is 0.78 as of Dec. 2025, which is 875% above its 10-year median of 0.08. GuruFocus rates ASX:MVP with a GF Score™ of 51/100 and a GF Value™ of A$0.65 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 690 Drug Manufacturers companies, Medical Developments International ranks better than 69.42% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
ASX:MVP'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.6 Med: 0.08 Max: 4.16
Current: 0.69
During the past 13 years, the highest Debt-to-EBITDA Ratio of Medical Developments International was 4.16. The lowest was -0.60. And the median was 0.08.
ASX:MVP's Debt-to-EBITDA is ranked better than 69.42% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs ASX:MVP: 0.69
Medical Developments International (ASX:MVP) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Medical Developments International Debt-to-EBITDA Related Terms
Medical Developments International Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Medical Developments International's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medical Developments International Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medical Developments International's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Medical Developments International's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Medical Developments International (ASX:MVP) has a Debt-to-EBITDA of 0.78 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medical Developments International. This is 875% above median its historical median of 0.08. According to the industry distribution chart, Medical Developments International ranks #211 out of 690 companies in the Drug Manufacturers industry, placing it in the top 30.6%.
Is Medical Developments International's Debt-to-EBITDA too high?
Medical Developments International's current Debt-to-EBITDA of 0.78 is 875% above median its 10-year median of 0.08. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Medical Developments International's value of 0.78 is 53.3% below this industry median. Based on the distribution chart, Medical Developments International ranks #211 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Medical Developments International has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #211 out of 690 companies for Debt-to-EBITDA. This puts Medical Developments International in the upper half of its industry. The industry median Debt-to-EBITDA is 1.67. Medical Developments International's value of 0.78 is 53.3% below this benchmark. While the company's 10-year median is 0.08 vs. the industry median of 1.67, Medical Developments International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medical Developments International's current Debt-to-EBITDA of 0.78 is 53.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Medical Developments International. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current Debt-to-EBITDA is 0.78, which is 875% above median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (ASX:MVP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.65, compared to a current price of A$0.39 — trading 40% below its estimated fair value. The current Debt-to-EBITDA is 0.78, which is 875% above median its 10-year median of 0.08 and 53.3% below the Drug Manufacturers industry median of 1.67. Medical Developments International's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Medical Developments International (ASX:MVP), the current Debt-to-EBITDA is 0.78 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (ASX:MVP) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of A$0.39 is trading 40% below its estimated GF Value™ of A$0.65.
GuruFocus considers Medical Developments International to be Significantly Undervalued.
Key valuation signals for ASX:MVP:
Debt-to-EBITDA: 0.78 (875% above median its 10-year median of 0.08)
GF Value™: A$0.65 vs. price of A$0.39 (40% below fair value)
Industry Position: 53.3% below the Drug Manufacturers median (#211 of 690)
No single metric tells the full story. See the ASX:MVP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Business Description
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
51GF Score
Get the complete analysis for ASX:MVP
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MVP has been successfully added to your 
